Opsoclonus-myoclonus syndrome following long-term use of cyclosporine

Clin Toxicol (Phila). 2018 May;56(5):373-376. doi: 10.1080/15563650.2017.1375511. Epub 2017 Sep 14.

Abstract

Background: Cyclosporine A (CsA) is a widely used immunosuppressive agent that may provoke unexpected neurologic complications. The mechanism is unclear and variable intervals have been reported between CsA administration and onset of the related side effects. Here, we describe a case of delayed-onset CsA neurotoxicity presenting as opsoclonus-myoclonus syndrome (OMS).

Case details: A 37-year-old woman with a two-week period of opsoclonus and upper extremity myoclonus was admitted to our hospital. The patient had been taking CsA for 17 years after receiving a kidney transplant. Further evaluation did not reveal any other abnormalities. Seven days after switching from CsA to tacrolimus, in the absence of additional immune-modulating therapy, her neurologic symptoms improved considerably.

Conclusion: This is the case of delayed, long-term complications of CsA presenting as OMS. Symptoms resolved by substituting CsA with another immunomodulating drug. The etiology of the neurologic complications may involve paradoxically-enhanced delayed-type hypersensitivity.

Keywords: Cyclosporine; neurotoxicity; opsoclonus-myoclonus syndrome.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Cyclosporine / adverse effects*
  • Cyclosporine / therapeutic use
  • Female
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Immunosuppressive Agents / therapeutic use
  • Kidney Transplantation / adverse effects
  • Opsoclonus-Myoclonus Syndrome / chemically induced*

Substances

  • Immunosuppressive Agents
  • Cyclosporine